News Hainan Poly Pharm. Co., Ltd

Equities

300630

CNE100002N10

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
12.35 ^CNY	-18.75%		-.--%	-45.40%

May. 14	China Grants Registration Approval for Antibacterial Drug	MT
May. 06	Hainan Poly Pharm Gets GMP Certificate From Saudi Authorities	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

China Grants Registration Approval for Antibacterial Drug	May. 14	MT
Hainan Poly Pharm Gets GMP Certificate From Saudi Authorities	May. 06	MT
Hainan Poly Pharm Gets Nod to Market Voriconazole Injection in Sweden	Apr. 08	MT
Hainan Poly Pharm Gets Nod to Market Skin Infection Drug in Germany	Apr. 04	MT
Hainan Poly Pharm's Brivaracetam Injection Gets FDA's Nod to Enter US Market; Shares Up 3%	Mar. 04	MT
Hainan Poly Pharm's Epilepsy Drug Gets FDA's Greenlight to Enter US Market	Feb. 19	MT
Hainan Poly Pharm to Apply For Up to 3.8 Billion Yuan Credit Line	Jan. 11	MT
Hainan Poly Pharm Gets Nod to Market Pantoprazole Sodium for Injection in Singapore	Dec. 12	MT
Hainan Poly Pharm. Co., Ltd(SZSE:300630) dropped from Shenzhen Stock Exchange Component A Share Index	Dec. 11	CI
Hainan Poly Pharm. Co., Ltd(SZSE:300630) dropped from Shenzhen Stock Exchange Component Index	Dec. 11	CI
Hainan Poly Pharm. Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Hainan Poly Pharm's Gets US FDA Nod to Market Iopamidol Injection	23-10-09	MT
Hainan Poly Pharm Gets Approval to Market Fluconazole Dry Suspension in US	23-09-25	MT
Tranche Update on Hainan Poly Pharm. Co., Ltd's Equity Buyback Plan announced on April 25, 2023.	23-09-15	CI
Hainan Poly Pharm. Co., Ltd's Equity Buyback announced on April 25, 2023 has closed with 1,426,700 shares, representing 0.33% for CNY 30.03 million.	23-09-13	CI
Hainan Poly Pharm's Unit Passes US FDA's On-Site Inspection	23-09-11	MT
Hainan Poly Pharm. Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Hainan Poly Pharm's Unit Passes Regulator's GMP Inspection	23-08-07	MT
Hainan Poly Pharm Wins FDA Nod to Market Azithromycin Variant in US	23-07-31	MT
Hainan Poly Pharm. Co., Ltd Announces Dividend Implementation of Cash Dividend for 2022, Payable on 18 July 2023	23-07-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Hainan Poly Pharm. Co., Ltd

Equities

300630

CNE100002N10

Summary

Filters